| Description | Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer. |
| In vitro | Tremelimumab 对 CTLA-4-Ig 的结合亲和力高于 CD28-Ig，显示出对猕猴和人类的特异性。它不与人类白细胞 FcγR 结合，从而降低了细胞因子释放综合征的风险。有趣的是，当用葡萄球菌肠毒素 A 刺激时，Tremelimumab 以浓度依赖的方式增强 IL-2 的产生，展现其调节 T 细胞反应的能力。[1] |
| Synonyms | Ticilimumab, CP-675206 |
| molecular weight | N/A |
| CAS | 745013-59-6 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76. |